Abstract
A series of pyran 1–6 and polyhydroquinoline derivatives 7–9 are synthesized targeting anticancer agents for clinical trials. Their structures are characterized by IR, 1H NMR, and HRMS spectra, and single crystal X-ray crystallography. Their anticancer activity against four human osteosarcoma cells (Saos-2, MG-63, 143B, and U2-OS) is evaluated in vitro using the MTT assay. The compounds 7–9 demonstrate high anticancer activity against the four cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
